It was a bit of a clayton's downgrade. was only because they havent yet found a distributor in Germany for Aridol which implies sales are about 6 months behind schcedule. followers of the stock know that Aridol is peanuts compared to the Bronchitol market.
incredibly he also lowered earnings becuase of the rising A$ which is classic. this company is still some way away from selling in such large quantities that forex makes a huge difference. who knows what the FX rate will be then (also why cant they put theri prices up?)
it was funny reading the report. the analyst was itching to put a $4.00+ valuation on it but couldn't because he is waiting for the results announcement. it's almost like he has the next report ready to publish for when the results come out anytime in the next 8 weeks. he'll then go back to clients and say i told you so.
the analyst was quoted in the Fin Review earlier in the week on PXS.
It was a bit of a clayton's downgrade. was only because they...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
